Scienture Holdings (SCNX) Secures GPO Agreements for Arbli Hypertension Drug
Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday that it has formalized multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL. This represents a significant step in expanding access to this medication for patients across the U.S.
Access to Healthcare Institutions
These agreements will provide Scienture with access to more than 2,500 healthcare institutions throughout the U.S., including hospitals, clinics, and long-term care facilities. This broad reach aims to help the company penetrate an estimated 20% of the U.S. institutional market with its novel liquid formulation of a widely prescribed hypertension medication.
Formulary Access and PBM Agreement
Two weeks prior, Scienture formalized a commercial Pharmacy Benefit Manager (PBM)-led Group Purchasing Organization (GPO) rebate agreement. This agreement is expected to advance the process of securing formulary access with health plans that cover more than 100 million lives. This deal could significantly increase the availability of Arbli to a large patient population.
Arbli: The First FDA-Approved Liquid Losartan
Arbli is FDA-approved for the treatment of hypertension in patients six years and older. It's also approved for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. Notably, Arbli is the first and only FDA-approved, ready-to-use oral liquid losartan available in the U.S.
Management Perspective
“By gaining access to more than 2,500 healthcare institutions, we are positioning Arbli to reach the patients and providers who need it most,” said Narasimhan Mani, president and co-CEO of Scienture.
Advantages of Arbli Formulation
Arbli is the first and only liquid formulation of losartan on the market that does not require compounding, offering reduced dosing volume and a long-term shelf life at room temperature storage. This provides advantages for both patients and healthcare providers.
Intellectual Property and Market Data
Arbli has two issued patents from the USPTO, which are also listed in the FDA Orangebook. According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately $256 million in annual sales and a prescription volume of 71 million (TRx), with all currently marketed products available only in oral solid form. This creates a significant market opportunity for a liquid formulation like Arbli.
Recent Financial Activity
In August, Scienture announced a registered direct offering of 3.225 million shares at $1.20 per share, with gross proceeds of approximately $3.9 million. This capital raise may be used to support the commercial launch of Arbli.
SCNX Stock Performance
SCNX Price Action: Scienture Holdings shares were down 0.16% at $0.84 during premarket trading on Wednesday. The stock is trading near its 52-week low of $0.69, according to Benzinga Pro data.
